HOOK General/Rough Short Position Analysis
Overall:
* Negative EPS
* June 7th conference Asco will most likely lead to a double-top.
* The "surge" is starting to end, if not has already ended. Share price should return to anywhere between $8-11, possibly even lower.
* Medical breakthroughs, as a whole, when it comes to cancers, which this company focuses on, are slow, unlikely, and uncommon. And I suspect, the share price will not be Mooning, anytime soon.
* Negative EPS
* June 7th conference Asco will most likely lead to a double-top.
* The "surge" is starting to end, if not has already ended. Share price should return to anywhere between $8-11, possibly even lower.
* Medical breakthroughs, as a whole, when it comes to cancers, which this company focuses on, are slow, unlikely, and uncommon. And I suspect, the share price will not be Mooning, anytime soon.
Pernyataan Penyangkalan
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.